Published in Immunol Cell Biol on December 01, 2004
Injectable polymer microspheres enhance immunogenicity of a contraceptive peptide vaccine. Vaccine (2006) 1.18
PLGA nanoparticle-mediated delivery of tumor antigenic peptides elicits effective immune responses. Int J Nanomedicine (2012) 1.01
Linear and branched glyco-lipopeptide vaccines follow distinct cross-presentation pathways and generate different magnitudes of antitumor immunity. PLoS One (2010) 0.97
InCVAX--a novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity. Cancer Lett (2015) 0.82
Safety and Immunogenicity of a Human Papillomavirus Peptide Vaccine (CIGB-228) in Women with High-Grade Cervical Intraepithelial Neoplasia: First-in-Human, Proof-of-Concept Trial. ISRN Obstet Gynecol (2011) 0.81
Immune stimulating photoactive hybrid nanoparticles for metastatic breast cancer. Integr Biol (Camb) (2013) 0.81
Nanomaterials in the application of tumor vaccines: advantages and disadvantages. Onco Targets Ther (2013) 0.80
Intraoperative subcutaneous or intrasplenic vaccination with modified autologous tumor cells leads to enhanced survival in a mouse tumor model. J Cancer Res Clin Oncol (2006) 0.79
Aluminum nanoparticles enhance anticancer immune response induced by tumor cell vaccine. Cancer Nanotechnol (2010) 0.76
Synthetic self-adjuvanting glycopeptide cancer vaccines. Front Chem (2015) 0.76
Anti-ganglioside antibodies induced in chickens by an alum-adsorbed anti-idiotype antibody targeting NeuGcGM3. Front Immunol (2013) 0.75
Innate-immunity cytokines induced by very small size proteoliposomes, a Neisseria-derived immunological adjuvant. Clin Exp Immunol (2007) 0.75
Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther (2011) 1.87
Clinical evidences of GM3 (NeuGc) ganglioside expression in human breast cancer using the 14F7 monoclonal antibody labelled with (99m)Tc. Breast Cancer Res Treat (2005) 1.05
T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies. Cancer Immunol Immunother (2007) 1.02
Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function. Int Immunol (2008) 1.00
Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy. Expert Opin Biol Ther (2010) 0.98
Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells. Cancer Immunol Immunother (2005) 0.95
Inhibition of tumor-induced myeloid-derived suppressor cell function by a nanoparticulated adjuvant. J Immunol (2010) 0.89
Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for Th1 induction and dendritic cell activation. Vaccine (2004) 0.89
Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for generation of CTL responses to peptide and protein antigens. Vaccine (2005) 0.85
Adjuvants and myeloid-derived suppressor cells: enemies or allies in therapeutic cancer vaccination. Hum Vaccin Immunother (2014) 0.81
Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors. Vaccine (2005) 0.80
Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge. Cancer Immunol Immunother (2008) 0.79
Simple multichannel system for the measurement of the net water flux across biological tissues. Comput Methods Programs Biomed (2006) 0.78
Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine. Hum Vaccin Immunother (2014) 0.77
Very small size proteoliposomes derived from Neisseria meningitidis: an effective adjuvant for dendritic cell activation. Vaccine (2006) 0.76